Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.
Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. Ryerson CJ, et al. Among authors: mittoo s. Can Respir J. 2015 Nov 2:17206. Online ahead of print. Can Respir J. 2015. PMID: 26523546 No abstract available.
The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.
Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. Ryerson CJ, et al. Among authors: mittoo s. Can Respir J. 2016;2016:3562923. doi: 10.1155/2016/3562923. Epub 2016 Apr 5. Can Respir J. 2016. PMID: 27445528 Free PMC article.
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Saketkoo LA, et al. Among authors: mittoo s. Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Thorax. 2014. PMID: 24368713 Free PMC article.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.
Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Saketkoo LA, et al. Among authors: mittoo s. J Rheumatol. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. J Rheumatol. 2014. PMID: 24488412 Free PMC article. Review.
72 results